Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42

Benzinga Newsdesk www.benzinga.com Neutral 51.4%

Neg 0% Neu 51.4% Pos 0%

Raymond James analyst Thomas Deal initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $42.